We are moving forward (very slowly) but as each step is taken we are a step closer. It's clear that nothing disastrous is happening within the trials, otherwise they wouldn't be opening more. Kefi starting to gather momentum, which means top slice and top up here. Lupazor patented for another 10 years, reading around pharmaceuticals, I feel extremely confident of a buy out here if approved. I will not band around the figures, but lupazor appears to have taken a step forward in medicine, being able to treat auto-immune diseases in a totally different way. The adaption to treat other diseases offers more scope and development. If the results are repeated it will be great for the sufferers of this and other diseases. For these reasons as well as 10 years of treating with little competition, I feel very optimistic of a buyout.
Those two trades look like someone has a bit of ocd about round numbers. It's been about 8weeks since European sites opened, approximately that's how long it took to start dosing in America. Surely we should be close. We need 200 patients to complete the study. Does anyone/could we find out how many have actually been dosed in America up to press?
From the results last week - sounds like we will be getting some more data and an RNS: (***emphasis*** added)
Announced Today: Prof. Sylviane Muller: London Lupuzor Symposium June 8 & 9, 2016
-- A number of key symposiums will be hosted during this two day event where Prof. Muller will present on the unique 'Mechanism of Action' of Lupuzor(TM), also known by its chemical name 'Forigerimod' or 'P140'. ***Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.***
Absolutely - it the nature of the beast. It's going to be in the dark until final results are approved. The all the precious results are there, but as far as a drug goes - this is as de-risked as it can be.
There will be lots of buying opportunity over the next year, but I can't see this dropping out of the 20s, more likely creep into and hold 30s.
Actually when you think about it, every month that passes with no news, is actually good news for lupazor. I do think that should they start spending on the other drugs, they will need to raise funds before the end of the trials. £8mln doesn't go a long way really in pharmaceuticals
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.